Roche Acquires Poseida for Up to $1.5B to Expand Off-the-Shelf CAR-T Cell Therapies

Roche's acquisition of Poseida Therapeutics for up to $1.5 billion marks a significant step in expanding its portfolio in allogeneic CAR-T therapies. This strategic move follows a $110 million partnership between the two companies in 2022, focusing on licensing agreements for cell therapy candidates, including the development of treatments like P-BCMA-ALLO1 for multiple myeloma[1][2]. The acquisition offers Roche a full suite of Poseida's cell therapy pipeline and access to its nonviral gene editing technology, which aims to increase the safety and efficacy of CAR-T treatments by emphasizing the inclusion of T stem cell memory cells[2]. Analysts view Roche’s strengths in oncology as a natural fit for Poseida’s innovative technologies, and Roche plans to utilize Poseida’s capabilities to deepen its effort to advance treatments in oncology, immunology, and neurology[1][3].